Skip to content

    Pfizer Limited

    PFIZERGood
    Healthcare·5 Aug 2020
    Management Summary

    Pfizer India delivered a resilient performance in Q1 FY21 despite significant COVID-19 headwinds. While the hospital and pediatric vaccine segments were severely impacted by lockdowns, the core Internal Medicine portfolio grew strongly following a successful sales model restructuring. Exceptional cost control and tax benefits led to double-digit profit growth despite a revenue contraction.

    Highlights

    7

    • Revenue from operations stood at ₹515 crores, a decline of 5.3% YoY due to COVID-19 impact on hospital and vaccine segments.

    • Net Profit (PAT) grew by 10% YoY to ₹124 crores, supported by a lower effective tax rate of 25% vs 30% last year.

    • EBITDA margin expanded significantly to 37% from 31% YoY, primarily driven by a sharp reduction in travel and promotional expenses.

    • Internal Medicine business (55% of revenue) logged healthy growth of 13% following a major go-to-market restructuring in Q4 FY20.

    • Hospital (Critical Care) business declined by 41% as ICU wards were prioritized for COVID patients and elective surgeries were postponed.

    • Vaccine business declined by 23% as pediatric clinics remained closed during the lockdown, though adult vaccination showed resilience.

    • The company declared and paid a special Platinum Jubilee dividend of ₹320 per equity share in May 2020.

    Concerns

    1

    • Prolonged impact on Hospital/Critical Care segment

    Key financials

    Single quarter

    05 metrics
    1. 01Revenue from Operations₹515 Cr-5.3%YoY
    2. 02EBITDA Margin37%
    3. 03Profit from Operations₹159 Cr+13%YoY
    4. 04PAT₹124 Cr+10%YoY
    5. 05Other Income₹17 Cr-52.8%YoY

    Segment breakdown

    Internal Medicine
    13% Revenue Growth55% Revenue Share
    Hospital (Critical Care)
    -41% Revenue Growth
    Vaccines
    -23% Revenue Growth
    Consumer Healthcare
    -27% Revenue Growth
    List

    Guidance & targets

    4
    CategoryTargetPriority
    Margin
    EBITDA Margin Band
    25% to 30%
    		Medium
    Revenue
    Minipress XL Annualized Sales
    ₹70-80 crores
    		High
    Revenue
    Nexium Sales Growth
    ₹40 crores
    		Medium
    Revenue
    Meronem Annual Sales Ambition
    ₹100 crores
    		Medium

    Risks & concerns

    5
    RiskSeverity

    Prolonged impact on Hospital/Critical Care segment

    ICUs remain full with COVID patients, leaving little room for elective surgeries and transplants that drive antibiotic sales. — Management acknowledged

    high

    Normalization of EBITDA margins

    Current 37% margins are unsustainable as travel and promotional activities resume. — Management acknowledged

    medium

    Divestment of Consumer and Upjohn portfolios

    These portfolios (contributing ~4% of sales) will be divested at some point, leading to a small revenue leak. — Management acknowledged

    low

    Areas of Evasion(2)

    • Specific details on the COVID vaccine's commercial path in India.
    • Specific therapeutic segments for the 5-year new product pipeline.

    Q&A highlights

    3

    “I welcome the competition... I believe the market will expand and everyone will have a share of the pie. We are still going to be the only 13 valent in the country.”

    Investors were concerned about Serum Institute's entry into the private market; management believes low penetration allows for multiple players.

    asked by Gagan Thareja

    2 min read5 chapters

    Detailed Narrative

    01

    Segmental Divergence Under COVID-19

    The quarter was defined by a sharp split in performance. The Internal Medicine segment, which includes legacy brands like Becosules and Corex, grew 13% YoY. In contrast, the Hospital business plummeted 41% as ICU wards were dedicated to COVID-19 patients, halting elective surgeries. Vaccines also saw a 23% decline as pediatric footfalls vanished during the lockdown. Management estimated the net revenue impact of COVID-19 at approximately ₹57 crores for the quarter.

    02

    Strategic Restructuring of Internal Medicine

    In Q4 FY20, Pfizer executed a major restructuring of its Internal Medicine business (55% of revenue). The new model uses a mix of 100% Pfizer FTEs in select territories and a 100% contract sales model in others. This 'feet on the ground' approach allowed the company to clock 100% of its budget during the peak COVID months of April-June, signaling a successful turnaround for this previously 'see-saw' business.

    03

    Margin Expansion and Sustainability

    EBITDA margins reached an exceptional 37% in Q1, up from 31% YoY. This was largely due to 'other expenses' falling to 13% of sales (₹65 crores) from 19% (₹100 crores) as travel and physical doctor conferences were replaced by digital engagement. CFO Milind Patil cautioned that while some digital efficiencies will remain, margins are expected to normalize📎 to the 25-30% range as competitive intensity and field activities return.

    04

    Innovative Portfolio and Pipeline

    Pfizer continues to shift toward its global innovative portfolio, which now accounts for 48.6% of sales compared to 36.3% in 2016. New products launched in FY20 contributed ₹170 crores (8% of sales). Zavicefta, launched last year, reached ₹32-33 crores in sales. Management remains focused on maximizing the global Pfizer portfolio in India, though they were tight-lipped about specific upcoming launch dates.

    05

    Vaccine Dynamics and Competition

    While pediatric Prevenar sales fell 25% in Q1, adult vaccination (₹11 crores in Q1) is viewed as a major future growth driver due to increased health awareness. Addressing the entry of Serum Institute's pneumococcal vaccine, management expressed confidence in Prevenar's 20-year efficacy record and 13-valent differentiation, believing the new competition will primarily serve to expand a currently under-penetrated market.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.